Please ensure Javascript is enabled for purposes of website accessibility

Why Ziopharm Oncology Soared 49% In February

By Todd Campbell - Mar 8, 2016 at 3:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A second generation CAR-T approach has moved into human trials.

SOURCE: MD ANDERSON CANCER CENTER

What: After reporting that the first patient has been dosed with its second generation CAR-T cancer killing therapy on Feb. 9 and releasing its fourth quarter financials on Feb. 24, Ziopharm Oncology (ZIOP 4.84%) sky-rocketed 49.4% in February, according to S&P Global Market Intelligence.

So what: The initiation of human trials for Ziopharm Oncology's second generation CAR-T therapy is big news because this next-generation approach includes the Sleeping Beauty technology that the company and its partner Intrexon (PGEN 5.22%) licensed from MD Anderson in January 2015.

Previously, T-cells were modified to find and destroy B-cell cancers by an expensive and time-consuming process that uses viruses to "teach" T-cells to recognize CD-19, a B cell specific protein.

Instead, Sleeping Beauty is a non-viral approach that relies on a DNA sequence that can change its location within the genome. After a chimeric antigen receptor is developed for each patient's specific cancer, the sequence is partnered up with Sleeping Beauty and introduced to patients via electroporation, which allows the DNA to enter the T-cells.

Ziopharm Oncology thinks that using Sleeping Beauty to deliver its CARs will reduce the cost and time associated with re-engineering a patient's immune system, in turn, making this second-generation approach more viable than the previous generation.

On Feb. 24, Ziopharm Oncology also updated investors on its financial picture, reporting that research and development and SG&A expenses resulted in the company losing $9.5 million and $120 million in the fourth quarter and in 2015, respectively.

Now what: Ziopharm's teaming up Sleeping Beauty with Intrexon's Rheoswitch technology, which allows T-cell activity to be turned on and off as necessary, could allow the company to leapfrog other CAR-T competitors, including Juno Therapeutics and Kite Pharma that are similarly developing B cell therapies.

However, Ziopharm Oncology's trials are in the early stages of human clinical testing and cancer drug development is complex and costly. As a result, investors might want to temper their optimism and keep a close eye on the company's clinical trial progress. Ziopharm Oncology should have additional data from brain cancer, breast cancer, and B-cell trials available in the coming year.

Investors should also keep tabs on the company's cash burn this year. Although the $140.7 million in cash on its books exiting December should give it the financial flexibility it needs for now, equity markets are less willing to provide funding to biotech stocks than they were a year ago, and that could make it a bit tougher to raise additional money to finance studies in the future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ZIOPHARM Oncology, Inc. Stock Quote
ZIOPHARM Oncology, Inc.
ZIOP
$1.30 (4.84%) $0.06
Precigen, Inc. Stock Quote
Precigen, Inc.
PGEN
$1.41 (5.22%) $0.07
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
JUNO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.